273 related articles for article (PubMed ID: 35034861)
1. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
2. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Samuel E; Lie G; Balasubramanian A; Hiong A; So Y; Voskoboynik M; Moore M; Shackleton M; Haydon A; John T; Mitchell PLR; Markman B; Briggs P; Parakh S
Clin Lung Cancer; 2021 May; 22(3):e425-e430. PubMed ID: 32778511
[TBL] [Abstract][Full Text] [Related]
3. Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
Veron M; Pierret T; Pérol M; Bettega F; Benet J; Denis N; Moro-Sibilot D; Swalduz A; Toffart AC
Respir Med Res; 2023 Jun; 83():101004. PubMed ID: 37037058
[TBL] [Abstract][Full Text] [Related]
4. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
7. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
8. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
9. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.
Ksienski D; Wai ES; Croteau NS; Freeman AT; Chan A; Fiorino L; Poonja Z; Fenton D; Patterson T; Irons S; Lesperance M
J Geriatr Oncol; 2020 Jun; 11(5):807-813. PubMed ID: 31937494
[TBL] [Abstract][Full Text] [Related]
10. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
11. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
13. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
18. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Goldstein DA; Ratain MJ; Saltz LB
JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
[No Abstract] [Full Text] [Related]
19. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
20. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
Dudnik E; Moskovitz M; Agbarya A; Gottfried T; Shochat T; Urban D; Zer A; Rotem O; Moore A; Yust S; Peled N; Wollner M; Bar J;
Int J Cancer; 2021 Mar; 148(5):1183-1191. PubMed ID: 32875571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
